Press release
Investigation announced for Long-Term Investors in Instil Bio, Inc. (NASDAQ: TIL) over potential Wrongdoing
An investigation on behalf of investors in Instil Bio, Inc. (NASDAQ: TIL) shares over potential wrongdoing at Instil Bio, Inc.
Investors who purchased shares of Instil Bio, Inc. (NASDAQ: TIL) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Instil Bio, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Dallas, TX based Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. On October 31, 2022, before market hours, Instil Bio, Inc.issued a press release entitled "Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing" which announced the pause and that the pause was due to "a recent decrease in the rate of successful manufacturing of ITIL-168, resulting in the inability to dose some patients whose individual product of ITIL-168 was not successfully manufactured." Further, the Company announced that "[a]lthough no manufacturing failures have been observed to date in the ongoing Phase 1 trial of ITIL-306, the Company has also voluntarily paused enrollment in this trial as part of its overall manufacturing analysis." The Company also announced that it "intends to provide an update on the manufacturing analysis by early Q1 2023."
Shares of Instil Bio, Inc. (NASDAQ: TIL) declined from $5.26 per share on October 28, 2022, to $2.46 per share on November 1, 2022.
Those who purchased shares of Instil Bio, Inc. (NASDAQ: TIL) have certain options and should contact the Shareholders Foundation.
Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in Instil Bio, Inc. (NASDAQ: TIL) over potential Wrongdoing here
News-ID: 2911443 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Instil
TIL Therapy Market to Reach USD 2.14 Billion by 2034, Growing at 17.8% CAGR
Introduction
Tumor-Infiltrating Lymphocyte (TIL) therapy represents one of the most promising advancements in cancer immunotherapy. By harnessing and expanding a patient's own immune cells to fight tumors, TIL therapy has demonstrated strong clinical potential in treating solid tumors such as melanoma, lung cancer, and cervical cancer.
Unlike CAR-T therapies, which have shown greater success in hematological malignancies, TIL therapy is uniquely positioned for solid tumor treatment-a segment that accounts for the majority…
TIL Therapy Pipeline Insight 2025: Harnessing Tumor-Infiltrating Lymphocytes to …
DelveInsight's "TIL Therapy - Pipeline Insight, 2025" provides an in-depth look at the rapidly expanding field of tumor-infiltrating lymphocyte (TIL) therapy, an adoptive cell therapy approach that utilizes a patient's own immune cells to recognize and attack tumors. Initially pioneered in melanoma, TIL therapy is now being explored across a wide range of solid tumors, offering a promising avenue for patients with limited treatment options.
The pipeline highlights next-generation TIL therapies…
VVC Clothing Redefines Premium Streetwear with Motivational Designs That Celebra …
Fashion Brand Combines Remarkable Style with Inspirational Messaging to Empower "1 of 1" Customer Experience
VVC Clothing, is a premium streetwear and activewear brand, is revolutionizing the fashion industry by creating designs specifically intended to instil motivation and ambition into every outfit. The brand's unique approach reinforces customers' individual identities while delivering remarkable style that serves as daily inspiration for fashion-conscious men and women.
VVC Clothing has built its reputation on the…
New Horizons in Global TIL Therapy Market Exploring Future Growth Potential, New …
The Latest research report on the Global TIL Therapy Market 2025 provides a comprehensive analysis of the current market landscape, with forecasts extending to 2032. This study combines qualitative and quantitative insights to highlight significant market developments, challenges, competitive dynamics, and potential opportunities and trends shaping the Global TIL Therapy Market. The report covers market size, recent trends, growth projections, market share, and development status. Additionally, it examines government policies,…
TIL Therapy Pipeline Assessment, 2023 Updates | In-depth Insights into the Clini …
As per DelveInsight's assessment, about 15+ prominent pharma and biotech giants are working on 15+ drugs in the TIL Therapy pipeline landscape globally.
"TIL Therapy Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the TIL Therapy Therapeutics Market.
The report provides a detailed description of the pipeline drugs, including the mechanism of action, type, stage, route of administration, molecule…
Investigation announced for Investors in Instil Bio, Inc. (NASDAQ: TIL) over pos …
An investigation was announced for investors of Instil Bio, Inc. (NASDAQ: TIL) shares over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Instil Bio, Inc. (NASDAQ: TIL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Instil Bio, Inc. regarding its business, its…
